Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus NATACYN.
ANCOBON vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic